Sagent Pharmaceuticals Inc. (SGNT) Hits New 52-Week High at $21.88
Shares of Sagent Pharmaceuticals Inc. (NASDAQ:SGNT) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $21.88 and last traded at $21.79, with a volume of 780,507 shares trading hands. The stock had previously closed at $21.74.
Several brokerages have issued reports on SGNT. Royal Bank Of Canada lowered Sagent Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Monday, July 11th. JPMorgan Chase & Co. restated a “hold” rating and issued a $18.00 target price on shares of Sagent Pharmaceuticals in a research note on Wednesday, May 4th. Zacks Investment Research upgraded Sagent Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Tuesday, July 12th. Jefferies Group restated a “hold” rating and issued a $15.00 target price (up from $13.00) on shares of Sagent Pharmaceuticals in a research note on Friday, June 17th. Finally, Raymond James Financial Inc. lowered Sagent Pharmaceuticals from a “buy” rating to a “market perform” rating in a research note on Tuesday, July 12th. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Sagent Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $18.54.
The firm’s market capitalization is $717.11 million. The company has a 50-day moving average of $19.45 and a 200-day moving average of $14.73.
An institutional investor recently raised its position in Sagent Pharmaceuticals stock. New York State Common Retirement Fund raised its stake in shares of Sagent Pharmaceuticals Inc. (NASDAQ:SGNT) by 27.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 232,271 shares of the company’s stock after buying an additional 50,258 shares during the period. New York State Common Retirement Fund owned 0.71% of Sagent Pharmaceuticals worth $3,695,000 at the end of the most recent quarter.
Sagent Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.